CSIMarket
 
Ani Pharmaceuticals Inc  (NASDAQ: ANIP)
 
Price: $73.2500 $0.42 0.577%
Day's High: $73.52999877929688 Week Perf: -3.17 %
Day's Low: $ 71.90 30 Day Perf: -7.56 %
Volume (M): 340,549 52 Wk High: $ 99.50
Volume (M$): $ 0 52 Wk Avg: $82.38
Open: $72.81 52 Wk Low: $70.15



 Market Capitalization (Millions $) 1,605
 Shares Outstanding (Millions) 22
 Employees 970
 Revenues (TTM) (Millions $) 978
 Net Income (TTM) (Millions $) 107
 Cash Flow (TTM) (Millions $) 93
 Capital Exp. (TTM) (Millions $) 19

Business Description


Ani Pharmaceuticals Inc. is an innovative specialty pharmaceutical company that focuses on the development, manufacturing, and commercialization of high-quality generic and branded prescription pharmaceuticals. The company was founded in 2002 and is headquartered in Baudette, Minnesota, United States.

Ani Pharmaceuticals operates in four main segments: Generic Pharmaceuticals, Branded Pharmaceuticals, Contract Manufacturing, and Specialty Pharmaceuticals. The Generic Pharmaceuticals segment develops and markets generic products that are equivalent to their brand-name equivalents but are lower-priced alternatives. The Branded Pharmaceuticals segment focuses on branded products that are marketed to specific niche markets, usually where there are no generic alternatives. The Contract Manufacturing segment provides contract manufacturing services to other pharmaceutical companies, utilizing the company's expertise in formulation development, analytical testing, and commercial-scale manufacturing. The Specialty Pharmaceuticals segment develops and markets specialty products that typically have lower competition, smaller markets, and higher margins than generic or branded products.

Ani Pharmaceuticals has a portfolio of over 100 generic and branded products covering several therapeutic categories, including oncology, cardiology, dermatology, pain management, and more. It markets its products through wholesalers, distributors, retailers, and other customers in the United States, Canada, and other international markets.

Apart from its product portfolio, Ani Pharmaceuticals has a state-of-the-art FDA-approved manufacturing facility that can produce several dosage forms such as tablets, capsules, creams, gels, and liquids. The company has a highly experienced team of scientists, researchers, and technicians who work relentlessly to develop new and innovative products that meet the evolving needs of the healthcare industry.

Ani Pharmaceuticals is committed to achieving high levels of growth through organic growth and strategic partnerships and acquisitions. The company has made several strategic acquisitions over the years to expand its product pipeline and enhance its manufacturing capabilities. It also partners with other pharmaceutical companies to develop and commercialize joint products.

In summary, Ani Pharmaceuticals Inc. is a leading specialty pharmaceutical company with a strong focus on the development, manufacturing, and commercialization of high-quality generic and branded prescription pharmaceuticals. The company has a diversified product portfolio, state-of-the-art manufacturing facility, and a highly experienced team of experts. It is committed to innovation, growth, and exceeding the expectations of its customers, employees, and shareholders.


   Company Address: 104 Carnegie Center Drive, Suite 300 Princeton 8540 NJ
   Company Phone Number: 759-1810   Stock Exchange / Ticker: NASDAQ ANIP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALLR        1.44% 
CPIX   -14.67%    
PFE        1.75% 
TEVA   -2.38%    
• View Complete Report
   



Product Service News

ANI Pharmaceuticals Bolsters Patient Care with FDA Approval of New Prefilled Cortrophin Gel Syringe and Reports Subst...

Published Tue, Jun 17 2025 2:48 PM UTC

ANI Pharmaceuticals Receives FDA Approval for Purified Cortrophin Gel Prefilled Syringe Amidst Strong Revenue GrowthIn a significant stride within the biopharmaceutical landscape, ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) recently announced the approval of its new presentation of Purified Cortrophin Gel (repository corticotropin injection USP) in a prefilled syringe format b...

Product Service News

On March 19, 2025, ANI Pharmaceuticals, Inc. (NASDAQ ANIP), a prominent player in the pharmaceutical indust...

Published Wed, Mar 19 2025 10:57 AM UTC

ANI Pharmaceuticals Unveils Nitazoxanide Tablets Amid Mixed Market Performance On March 19, 2025, ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), a prominent player in the pharmaceutical industry, announced the launch of Nitazoxanide Tablets, 500 mg, a significant addition to its portfolio. This product marks the company’s entry into the market for a generic version of the refer...

Contract

ANI Pharmaceuticals Enhances Financial Flexibility with Strategic Buyout of Royalty Obligation on ILUVIEN and YUTIQ

Published Tue, Mar 18 2025 10:54 AM UTC

In a significant financial maneuver poised to bolster its growth trajectory, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) recently announced the successful completion of a buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC. This strategic decision, finalized on March 18, 2025, involves a one-time payment of $17.25 million and is expected to yield substantial be...

Product Service News

ANI Pharmaceuticals Secures FDA Approval and Launches Prucalopride Tablets A Robust Year of Growth

Published Fri, Jan 3 2025 7:51 PM UTC

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has announced the successful launch of its generic Prucalopride Tablets, following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA). Prucalopride is the generic equivalent of the reference listed drug (RLD) Motegrity. This launch is notable not only for the introduction of...

Product Service News

ANI Pharmaceuticals Launches Combined Promethazine and Dextromethorphan Oral Solution for Enhanced Respiratory Reli...

Published Fri, Sep 13 2024 10:50 AM UTC

ANI Pharmaceuticals, Inc. has announced the successful launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, a novel therapeutic solution designed for symptom management in respiratory ailments. This formulation delivers effective antitussive and antihistaminic effects, presenting a significant advancement for healthcare providers and patie...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 15.29
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.64
Price to Sales (Expected) -
Price to Book 2.69
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.27
Working Capital Ratio 2.91
Leverage Ratio (MRQ) 1.5
Total Debt to Equity 0.5
Interest Coverage (TTM) 21.73
Debt Coverage (TTM) 0.91

Per Share Current
Earnings (TTM) 4.79 $
Revenues (TTM) 44.64 $
Cash Flow (TTM) 4.26 $
Cash 16.44 $
Book Value 27.25 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,008,638
Net Income per Employee (TTM) 109,896
Receivable Turnover Ratio (TTM) 3.68
Inventory Turnover Ratio (TTM) 2.69
Asset Turnover Ratio (TTM) 0.68

Profitability Ratios Current
Gross Margin (MRQ) 62.35 %
Operating Margin (MRQ) 15.21 %
Net Margin (MRQ) 8.65 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 24.04 %

Management Effectiveness Current
Return On Assets (TTM) 7.4 %
Return On Investment (TTM) 9.09 %
Return On Equity (TTM) 19.33 %
Dividend Yield -
Pay out Ratio (TTM) -



Ani Pharmaceuticals Inc's Segments
Sales of Cortrophin Gel    72.26 % of total Revenue
Sales of ILUVIEN and YUTIQ    14.27 % of total Revenue
Total sales of rare disease pharmaceutical products    86.53 % of total Revenue
Sales of Established Brands    9.07 % of total Revenue
Sales of Established Brand Royalties and Other Revenues    14.76 % of total Revenue
Total Sales of Rare Disease and Brands    110.37 % of total Revenue
Sales of generic pharmaceutical products    76.85 % of total Revenue
Sales of Generic Other Revenues    2.04 % of total Revenue
Total Sales of Generics and Other    78.89 % of total Revenue
Brands    4.47 % of total Revenue
Generics and Other    78.89 % of total Revenue
Rare Disease and Brands    110.37 % of total Revenue

  Ani Pharmaceuticals Inc Outlook

On February 28 2025 the Ani Pharmaceuticals Inc provided following guidance

ANI Pharmaceuticals Inc. has recently disclosed its financial performance for the fourth quarter and full year of 2024, highlighting impressive results that have surpassed expectations. The company, based in Baudette, Minnesota, revealed this information in a press release dated February 28, 2025.

In this announcement, ANI Pharmaceuticals not only celebrated their record achievements but also communicated a positive adjustment to their financial outlook for 2025. While the specifics of the enhanced guidance were not detailed in the announcement, the noteworthy increase signals the company’s confidence in its growth trajectory and operational effectiveness going forward.

The robust financ...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.